ArticleMedical microbiology and immunology2026
Simultaneous quantification of anti-Spike IgG subclasses against various SARS-CoV-2 variants using a multiplex serological assay.
Article in Medical microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research indicates that the composition of serum anti-SARS-CoV-2 Spike IgG subclass antibodies changes upon repeated exposure to viral Spike. These antibody subclass dynamics were suggested to impact adaptive immune responses and protection against infection. To characterize the role of the IgG subclass composition in the immune response to SARS-CoV-2, assays that measure virus variant-specific anti-Spike IgG subclass concentrations are needed. Here, we describe an easy-to-use serological method for quantifying anti-Spike IgG subclass antibodies against various SARS-CoV-2 variants in multiplex from less than 10 µL of serum. Our assay enables antigen-independent quantification, making it easily adaptable to emerging variants or other pathogens. We validated our method with 20 sera collected from 10 infection-naïve individuals after the second and third COVID-19 mRNA vaccination. We observed increasing anti-Spike IgG2 and, especially, IgG4 concentrations after the third immunization. More recent Spike variants preserved this pattern with decreased levels of total anti-Spike IgG. Our results showed a strong positive correlation with those from an established flow cytometry-based approach. Our method might help deepen our understanding of immune responses to SARS-CoV-2 and, moreover, help gauge the individual's protection from severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.